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Christine Neuveut, Yu Wei, Marie Annick Buendia*
Oncogenesis and Molecular Virology Unit, Institut Pasteur, Inserm U579, 28 rue du Dr Roux, 75724 Paris cedex 15, FranceThe hepatitis B virus (HBV) is a small enveloped DNA virus, high viral load is known to increase the risk of developing HCC [7],
which primarily infects hepatocytes and causes acute and persis-
tent liver disease. Epidemiological studies have provided over-
whelming evidence for a causal role of chronic HBV infection in
the development of hepatocellular carcinoma, but the molecular
mechanisms underlying virally-induced tumourigenesis remain
largely debated. In the absence of a dominant oncogene encoded
by the HBV genome, indirect roles have been proposed, including
insertional activation of cellular cancer-related genes by HBV
DNA integration, induction of genetic instability by viral integra-
tion or by the regulatory protein HBx, and long-term effects of
viral proteins in enhancing immune-mediated liver disease.
Recent genetic studies indicate that HBV-related tumours display
a distinctive proﬁle with a high rate of chromosomal alterations
and low frequency of b-catenin mutations. This review will dis-
cuss the evidence implicating chronic HBV infection as a causal
risk factor of primary liver cancer. It will also discuss the molec-
ular mechanisms that are critical for the tumourigenic process
due to long lasting infection with HBV.
 2009 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Approximately 2 billion people present evidence of past or pres-
ent infection with hepatitis B virus (HBV) over the world. With
more than 350 million chronic HBV carriers, this virus stands as
one of the most common human pathogens and it causes signiﬁ-
cant public health problems [1]. Despite the availability of an efﬁ-
cacious and safe hepatitis B vaccine [2], chronic HBV infection
remains the major aetiological factor of hepatocellular carcinoma
(HCC) worldwide with more than one half of HCC patients being
chronic carriers [3]. In recent studies conducted in Asia andNorth-
ern America, it was estimated that the lifetime risk of developing
HCC is increased by 25–37 times in HBsAg carriers compared to
non-infected populations [4,5]. Importantly, the ﬁrst effects of
mass vaccination have been detected in Taiwan with signiﬁcant
reduction of HBV-related HCC in vaccinated children [6]. AlthoughJournal of Hepatology 20
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occult infection [8–10]. In addition, inconsistent geographical
variations in HCC mortality and HBV surface antigen (HBsAg)
prevalence have been observed in endemic regions, suggesting
that other independent or cooperative factors might be impli-
cated. In highly endemic regions, particularly in South Africa
and Mainland China, synergistic effects of aﬂatoxin B1 (AFB1)
and HBV infection have been highlighted in several reports [11].
Hepatocellular carcinoma (HCC) is a common malignancy and
a leading cause of cancer death worldwide. Recent epidemiolog-
ical data have demonstrated that liver cancer incidence is contin-
uously rising and will continue to do so for more than a decade,
not only in Asia and Africa but also in North America and Europe
[3,12]. HCC generally presents with poor prognosis, and no effec-
tive treatment is available for most HCC patients because this
tumour remains refractory to current chemotherapeutic regi-
mens [13]. Moreover, HCC is frequently diagnosed when
advanced stage of the disease precludes local ablative or surgical
interventions that could improve patient outcome. In this con-
text, advances in our understanding of the molecular basis of
HCC are urgently needed to develop early tumour markers and
novel targeted agents with improved therapeutic efﬁciency
[14,15]. Here we review the molecular mechanisms linking
chronic hepatitis B to malignant transformation of liver cells.The HBV life cycle
HBV is the prototype member of a family of small enveloped DNA
virus called hepadnaviruses, which infect a restricted number of
mammals and birds. These viruses share a narrow host range and
preferential tropism for hepatocytes. The genome of hepadnavi-
ruses is a relaxed circular, partially double-stranded DNA genome
that replicates via an RNA intermediate [16] (Fig. 1). The HBV
genome is around 3.2 kb in length and presents a highly compact
genetic organization with 4 overlapping open reading frames
(ORFs) that cover the entire genome. The pre-S/S ORF encodes
the three viral surface proteins, the pre-C/C ORF encodes the e
antigen (HBeAg) and the core antigen (HBcAg), the P ORF encodes
the terminal protein (TP) and the viral polymerase that possesses
DNA polymerase, reverse transcriptase and RNaseH activities.
The X gene encodes a small protein that is essential for virus rep-
lication but whose function remains partially understood. Finally,
a viral protein termed HBSP has been shown to be encoded by a
spliced viral transcript [17].10 vol. 52 j 594–604
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Fig. 1. Schematic representation of the circular, partially double-stranded
HBV DNA genome. Both DNA strands of the duplex are held together by base-
pairing over 250–300 nucleotides at their 50 extremities. The unit length-strand
(minus strand) is covalently linked to the viral polymerase and bears a 9-
nucleotide redundant sequence at its extremities. The complementary strand
(plus strand) is linked to a capped oligoribonucleotide at its 50 end. The plus
strand is less than unit length and terminates at different positions resulting in
the presence of a single-stranded region of variable length. Two 11-bp repeats,
DR1 and DR2, located at the 50 ends of the minus and plus strands, play a critical
role in viral DNA replication. Four open reading frame carried by the minus strand
are represented by large arrows.
JOURNAL OF HEPATOLOGYAlthough many steps of hepadnavirus replication have been
elucidated (Fig. 2), the initial phases of hepatocyte infection,
namely virion attachment, uncoating, and entry remain poorly
deﬁned, and a cell-surface receptor has not been identiﬁed so
far. These limitations may be explained by the low efﬁciency of
HBV infection in few available in vitro systems. In the absence
of candidate receptor, a less conventional hypothesis has been
proposed, in which scavenging liver sinusoidal endothelial cells
(LSEC), rather than hepatocytes themselves, mediate the initial
uptake of the viral pathogen into the liver [18]. After viral entry,
the nucleocapsid is released into the cytoplasm and transported
along the microtubules to the nuclear membrane. Nuclear import
of the nucleocapsid through the nuclear pore complex appears to
be mediated by importins a and b, and it is followed by disinte-
gration of the nucleocapsids and liberation of the HBV genome in
the nuclear pore basket [19]. In the nucleus, the relaxed circular,
partially duplexed DNA genome is converted into a covalently
closed circular molecule: the cccDNA [20–22]. The cccDNA serves
as template for transcription of all viral RNAs, including the
pregenomic RNA (pgRNA) as well as subgenomic RNAs. This step
is critical for ampliﬁcation of the viral progeny and for maintain-
ing productive infection in the host. Four promoters and two
enhancers that are preferentially active in hepatocytes regulate
the transcription of viral RNAs, and the HBx protein has been
reported to play an essential role in activating HBV transcriptionJournal of Hepatology 201[23]. It has been shown that the cccDNA is organized into a mini-
chromosome harboring a chromatin-like structure in the nuclei
of infected cells [24]. This structure is known to be resistant to
anti-viral agents and might be responsible for viral rebound upon
withdrawal of anti-viral therapy [25]. Recently, a chromatin
immunoprecipitation-based methodology (ChIP/cccDNA assay)
has been established to analyze the transcriptional regulation
of the cccDNA minichromosome [26]. These studies led to dem-
onstrate that HBV replication is regulated by the acetylation sta-
tus of the cccDNA-bound H3/H4 histones, and that H3/H4
acetylation status is tightly correlated with the level of viremia
in the infected patient.
The regulatory protein HBx has been found to play a key role
in HBV transcription and replication. Early studies have shown
that HBx stimulates the activity of viral promoters and enhancers,
and that the closely related virus WHV deﬁcient for the expres-
sion of WHx cannot replicate in the animal host [27,28]. More
recently, it was found that the replication of X-deﬁcient HBV gen-
omes was strongly compromised in established cell lines and in
the mouse liver, and that HBx provided in ‘‘trans” was able to
restore HBV replication to wild-type levels [23,29–31]. In most
studies, this effect has been attributed to the transactivator activ-
ity of nuclear HBx protein.
It is worth noticing that HBV replication does not require a
step of viral DNA integration into host chromosomes. In the cyto-
plasm, the pgRNA is selectively packaged into progeny capsids
and reverse-transcribed by the viral polymerase into minus
strand DNA followed by the synthesis of relaxed circular DNA
(RC-DNA). Capsids containing RC-DNA can be either recycled
for intracellular cccDNA ampliﬁcation [32], or assemble with
the viral surface proteins in the endoplasmic reticulum to form
the viral particles that will be released from the cell [33,34]
(Fig. 2). So far, inspection of the viral genome has not led to iden-
tify a dominant viral oncogene, and accordingly, introduction of
the HBV genome into primary cells in culture or into transgenic
murine models has not provided convincing evidence of cell
transformation or liver tumourigenesis.Natural history of chronic HBV infection
The natural history of chronic hepatitis B infection is a dynamic
and complex process that can present a variable course, depend-
ing on a balance between viral parameters and host immune
response [1]. While 90% of infected newborns and 30% of infected
children develop chronic hepatitis B, only 5% of individuals
infected at the adult age remain chronically infected, illustrating
the primary role of the patient’s immune system. Recent consen-
sus statements have schematically classiﬁed chronic hepatitis B
into ﬁve phases: the ‘‘immune tolerant phase”, the ‘‘immune
active phase”, the ‘‘inactive HBV carrier state”, the ‘‘HBeAg-nega-
tive chronic hepatitis B” and ﬁnally the ‘‘HBsAg-negative phase”
[35,36].
Typically, the initial phase of chronic HBV infection is charac-
terized by HBeAg-positivity, high levels of HBV DNA in serum and
variable elevation of serum alanine aminotransferase (ALT). How-
ever, in a proportion of HBeAg-positive patients, ALT levels are
normal and liver damage is minimal despite high levels of HBV
replication. This state referred to as the ‘‘immune tolerant phase”
is frequent after perinatal infections and it can persist for years.
The ‘‘immune active phase” also referred as ‘‘chronic hepatitis B0 vol. 52 j 594–604 595
Fig. 2. Schematic representation of the HBV life cycle. HBV infects hepatocytes via an unknown cell-surface receptor. After virion entry and uncoating, nucleocapsids are
transported to the cell nucleus where RC-DNA is converted to cccDNA, which is used as template for the transcription of pregenomic and subgenomic RNAs. In the
cytoplasm, pgRNA is bound by the viral polymerase and packaged into nucleocapsids, where viral DNA is synthesized. Nucleocapsids can either assemble with envelope
proteins in the endoplasmic reticulum, or deliver viral DNA into the nucleus for cccDNA ampliﬁcation.
Reviewphase” is typiﬁed by elevated ALT levels, low levels of HBV DNA
in serum, and moderate to severe liver necroinﬂammation that
may progress to ﬁbrosis. While this phase can occur several years
after experiencing the ‘‘immune tolerant phase” in perinatally-
infected patients, it can be detected shortly after infection during
adulthood. Large cell dysplasia has been frequently found in
advanced chronic hepatitis B with increased activity. It involves
hepatocytes with senescent features and no sign of proliferative
or apoptotic activity, and develops during periods of frequent
neoplastic transformation, thus raising the possibility that it
might occur as a safeguard against the development of hepatocel-
lular carcinoma [37]. Senescence in tumourigenesis is regarded as
a defense mechanism and evasion of senescence is thought to
lead to malignancy [38].
Among patients in the ‘‘immune active phase”, a majority
eventually progress into the ‘‘inactive HBV carrier phase”,596 Journal of Hepatology 201characterized by loss of HBeAg, seroconversion to anti-HBe
antibodies and decline of serum HBV DNA to barely detectable
levels, as well as improvement of ﬁbrosis and inﬂammation
over time [35,39,40]. In prospective studies, this state has
been associated with a favorable long-term outcome [41].
However, up to one-third of patients will undergo seroconver-
sion to anti-HBe antibodies and transition to the ‘‘HBeAg-neg-
ative chronic hepatitis B state”, characterized by periodic
reactivation associated with ﬂuctuating levels of ALT and
HBV DNA, and active hepatitis with variable degree of ﬁbrosis.
This transition has been attributed to the occurrence of nucle-
otide substitutions in the precore and/or the basal core pro-
moter region that preclude expression of the e antigen [42].
Emergence of these HBV variants is associated with active
liver disease, and with a high risk of developing cirrhosis
and HCC. By contrast, loss of HBsAg in patients in the0 vol. 52 j 594–604
Fig. 3. Chronic HBV infection and hepatocarcinogenesis. HBV DNA integration into the host genome and persistent expression of viral proteins such as HBx and large
envelope protein (LHBs) can activate cellular cancer-related genes, induce oxidative stress and genetic instability. In the inﬂammatory context triggered by host immune
responses, the viral functions contribute to ceaseless hepatocyte destruction–regeneration, and provide a favorable ground for emergence of genetic and epigenetic
alterations leading to hepatocyte transformation.
JOURNAL OF HEPATOLOGY‘‘HBsAg-negative phase” has a favorable prognosis, although
HCC incidence remains higher than in non-infected popula-
tions [43]. This observation may be linked to the ﬁnding that
persistent traces of HBV DNA are often detectable in the blood
for many years after clinical recovery from acute hepatitis,
despite the presence of serum antibodies and HBV-speciﬁc
CTLs [44].
While a majority of liver cancers develop in cirrhotic livers,
a signiﬁcant fraction of HBV-related HCCs occurs in a back-
ground of chronic hepatitis B in the absence of liver cirrhosis.
The incidence of cirrhosis appears to be about 2-fold higher in
HBeAg-negative compared to HBeAg-positive chronic hepatitis
[45]. The lower rate of underlying cirrhosis in HBV-related
HCCs compared to other aetiologies argues for a more direct
role of HBV in the tumoural process. Additionally, distinctive
gene expression proﬁles have been detected in the non-tumo-
ural livers of chronic HBV carriers, such as activated expres-
sion of genes implicated in pro-apoptotic, inﬂammatory and
DNA repair responses, suggesting speciﬁc pathways triggered
by chronic hepatitis B [46,47]. Thus, besides the effects of host
immune responses, HBV replication might trigger various sig-
naling cascades in the infected hepatocyte (Fig. 3). Integration
of viral, host and environmental parameters with molecular
changes might lead to identify novel targeted strategies to
improve the management of chronic hepatitis B. Risk scores
have been established to estimate the risk of developing
HCC in less than 10 years after presentation. Such scores
based on age, gender, HBV DNA levels, core promoter muta-
tions and cirrhosis, can be used to identify high-risk patients
for treatment and screening of HCC [48].Journal of Hepatology 201Molecular mechanisms of hepatocarcinogenesis
With the recent availability of integrative systems biology
approaches, global insights into genetic alterations and molecular
proﬁles have been reported in large series of HCCs during the last
years. These studies have demonstrated a variety of genetic alter-
ations and marked heterogeneity of gene expression proﬁles
among HCC cases, suggesting that HCC might be one of the most
complex and heterogeneous solid tumours in humans [49–51].
Such heterogeneity is in agreement with the multiple aetiologies
of HCC and the long period of chronic inﬂammatory disease that
fosters the accumulation of genetic and epigenetic defects. Evi-
dence has been provided for deregulation of various signaling
pathways in HCC subsets, such as Wnt/b-catenin signaling [52],
and the p14ARF/p53 pathway [53], transforming growth factor
beta (TGF-b) signaling, Ras/MAPK signaling and the PTEN/Akt
and mTOR pathways [54] (reviewed in [50]). Additionally, altered
expression of growth factors such as HGF, IGFs and Amphyregu-
lin, as well as genes involved in angiogenesis may participate in
the development and progression of HCC (reviewed in [55]).
Aberrant activation of the Wnt/b-catenin pathway through
mutations in either b-catenin or Axin genes has been found in
20–40% of HCC cases, predominantly in HCV-associated tumours
and in the absence of viral aetiology [56–58]. Interestingly, HCCs
carrying mutant b-catenin display distinctive patterns, with
highly differentiated morphology comprising microtrabecular
and acinar architectures, low proliferative rate, and frequent
intrahepatic cholestasis but no steatosis [59]. This tumour type
also displays activated expression of liver metabolic enzymes
involved in glutamine synthesis, urea cycle and detoxiﬁcation0 vol. 52 j 594–604 597
Review
metabolism, which are normally expressed in perivenous hepato-
cytes [60,61]. Moreover, b-catenin mutation has been correlated
with a low rate of genetic instability [56,62].
TGF-b has a complex role in HCC; it is persistently induced
during hepatitis and promotes cirrhosis progression by accelerat-
ing the deposition of extracellular matrix (reviewed in [63]).
Moreover, persistent upregulation of TGF-b in HCC has been sug-
gested to accelerate neoplastic growth [64]. A bipartite role has
thus been ascribed to TGF-b, which has tumour suppressor func-
tions at early stages of liver damage, while at neoplastic stages,
TGF-b may switch from being a tumour suppressor into being a
tumour promoter that induces invasive and metastatic behav-
iour. Accordingly, blocking TGF-b using a kinase inhibitor of the
TGF-b receptor I has an anti-tumoural effect via the regulation
of neo-vascularization [65].
While oncogenic mutations of Ras are rarely seen in HCC,
aberrant activation of protein kinases has been implicated in
tumour initiation and progression. These kinases include PI3K–
AKT, Aurora kinase, and receptor tyrosine kinases of VEGF, EGF,
PDGF, Heregulin, and IGF-I [66]. Recent studies have suggested
a major role of mitogen-activated protein kinases (MAP kinases)
such as p38 and the c-Jun N-terminal kinase (JNK) in driving
uncontrolled proliferation and invasion of hepatic tumour cells
[67–69]. These factors represent interesting targets for therapeu-
tic intervention, as shown recently by the ﬁnding that sorafenib, a
multikinase inhibitor, provides substantial survival beneﬁts in
patients at advanced HCC stages [70]. Moreover, it has been
recently suggested that synergistic effects might be obtained in
combination therapy using sorafenib and rapamycin for simulta-
neous inhibition of the Ras and mTOR pathways [71].
Familial cancergeneswithhigh-penetrancemutationshavenot
been identiﬁed so far in HCC. However, recurrent mutations that
compromise p53 function have been evidenced in the TP53 gene
(17q13.1) in about 25% of primary HCCs [72]. Loss-of-function
mutations of the AXIN1 gene (16p13.3) have been detected in 7–
10% of cases, leading to the aberrant activation of Wnt signaling
and possibly other pathways [73]. Other mutations affecting the
RB, CDKN2A, PTEN or CDH1 genes have been found more rarely,
and epigenetic silencing mechanisms such as the methylation of
promoter sites may be responsible for the inhibition of tumour
suppressor functions, as also recently found for the activation of
the Ras and Jak/Stat pathways in HCC [74]. Mutations or deletions
of other candidates including NF2, Bax, FHIT, LKB1 and LRP1B have
been seen at very low frequency (less than 2–4% cases) [75].
The question of whether distinctive molecular mechanisms
operate in HBV-related HCCs has been addressed using genetic
approaches and microarray technologies for analyzing gene
expression proﬁles. It has been shown that HBV-related HCCs dis-
play higher rates of chromosomal alterations than HCCs related
to other risk factors [76]. Interestingly, recent studies have evi-
denced two major routes of hepatocarcinogenesis that differ by
the extent of genetic instability, one being predominant in
HBV-related tumours [57]. In this work, genetically unstable
tumours have been associated with HBV infection, poor differen-
tiation, p53 mutations, and an unfavorable prognosis. Extending
these observations, gene expression proﬁling has revealed that
HCC subclasses associated with HBV infection also display an
activation of the mitotic cell cycle, deregulated expression of
developmental and imprinted genes such as IGF2, as well as acti-
vation of the AKT pathway [62]. In different studies, molecular
classiﬁcation of HCC based on gene expression proﬁles has598 Journal of Hepatology 201unveiled the predominant importance of the tumour cell differ-
entiation status for deﬁning molecular subtypes and predicting
disease outcome [67,77]. More recently, a meta-analysis integrat-
ing transcriptome data from eight independent cohorts has led to
the identiﬁcation of three major molecular subclasses of HCC
associated with tumour differentiation and serum alpha-fetopro-
tein (AFP) levels [78]. Again, in this study, chronic HBV infection
was found to be signiﬁcantly associated with HCC clusters fea-
tured by moderate/poor differentiation of tumour cells. More-
over, molecular classiﬁcation of HBV-related HCCs has been
used to predict early recurrence, which is a golden standard to
determine the success of curative resection. The group with a
high risk of recurrence showed an increased expression of genes
involved in cell cycle progression, cell proliferation, migration
and motility, and in the Notch signaling pathway [79].
While signiﬁcant advances can be noted in our understanding
of the molecular basis of hepatocarcinogenesis, future studies
should be aimed at gaining a comprehensive view of the signaling
networks operating in liver cell transformation due to chronic
hepatitis B.Chronic HBV infection and liver oncogenesis
HBV mutants and genotypes
During the progression of chronic hepatitis B from the asymp-
tomatic carrier state to HCC, mutations accumulate in the viral
genome in the preS region and in the carboxy-terminal region
of the X gene, which overlaps with the enhancer II and the basal
core promoter (BCP) [80]. Whether the risk of developing HCC
may be inﬂuenced by the viral status of the patients, such as
HBV genotypes, hepatitis B e antigen (HBeAg) serostatus, and
mutations arising during chronic infections are important issues.
It has been shown that these parameters play important role, not
only in the progression of chronic liver disease, but also in the
response to anti-viral therapies [81–83].
While epidemiological studies are usually based on HBsAg
positivity, several case-control studies have pointed to HBeAg
as a potential predictive marker, with a higher prevalence of
HBeAg among patients with HBV-related HCC than among
matched HBsAg carriers. In a study of a large cohort of patients,
the relative risk of HCC was increased by 6-fold among patients
positive for both HBeAg and HBsAg compared with those positive
for HBsAg alone [84]. Thus HBeAg may be a useful marker of the
risk of cancer, probably because it reﬂects active HBV DNA repli-
cation. The differential oncogenicity of HBV genotypes has been
extensively analyzed. Important differences have been observed
in the prevalence of serum HBeAg, the levels of HBV DNA, and
the occurrence of precore or core promoter mutations between
genotypes B and C [85], and between genotypes Aa, Ae, and D
[86]. Evaluation of clinical and virological differences between
HCC patients infected with genotype B or genotype C in Japan
and Taiwan has given rise to divergent data [87,88]. Other studies
have concluded that HBV genotype C takes a more aggressive dis-
ease course than genotype B in HBeAg-positive patients [89], and
HBV genotype C infection (compared to genotype B) has been
found as an independent risk factor for HCC development [90].
By contrast, other studies have shown that the prevalence of
T1762/A1764 mutation in the basal core promoter increases with
the progression of liver disease, and that this mutation is signif-0 vol. 52 j 594–604
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icantly associated with the development of HCC, both in geno-
types B and C [85].
More recently, the notion that HBV genotypes and variants
might harbor different oncogenic potential has been strength-
ened by large-scale studies involving thousands of patients and
meta-analysis of compiled data. Statistically signiﬁcant correla-
tions with HCC occurrence were seen for mutations in the preS
region in HBV genotype C, and at positions C1653T in enhancer
II as well as T1753V and A1762T/G1764A in the basal core pro-
moter (BCP) in HBV genotype C. These mutations alone or in com-
bination can predict HCC development in 80% of cases [80].
Furthermore, the T1762/A1764 mutation can be detected in
plasma up to 8 years before HCC diagnosis; this mutation might
therefore be considered as a strong predictive biomarker [91].
HBV DNA integration into human chromosomes
HBV DNA integration into human host chromosomes occurs in
the infected liver since early stages of natural acute infections
[92,93]. Multiple integrations have been detected in chronic hep-
atitis tissues [94,95], and integrated HBV sequences have been
seen in most (about 80%) HBV-related HCCs [96,97]. In the
absence of complete genomes in virtually all HBV inserts, these
sequences cannot serve as template for viral replication.
HBV DNA integration sites in human HCCs have been localized
on almost all chromosomes, suggesting a random distribution
throughout the host genome [93,98]. These events could either
induce chromosome changes or act in cis on the expression or
function of nearby cellular genes. For a long time it has been
thought that HBV insertional mutagenesis is a rare event, and
that simple repetitive elements are hotspots for HBV insertion
in the human genome. However, evidence for a direct cis-acting
promoter insertion mechanism was ﬁrst provided in two inde-
pendent HCCs, in which the HBV insertion targeted either the ret-
inoic acid receptor-b (RAR-b) gene or the human cyclin A gene,
resulting in tumour-speciﬁc chimeric proteins endowed with
novel, pro-carcinogenic functions [99–102,103,104]. Thus, the
analysis of single HBV insertion sites has allowed identifying
new genes that play critical roles in the control of cell growth
and differentiation.
In recent studies, the view of random HBV integration has
been challenged by large-scale analysis of HBV DNA insertion
sites using the Alu-PCR approach. These studies revealed high
rates of gene targeting by HBV integration [105,106]. As previ-
ously shown for retroviruses [107,108], HBV DNA integration
appears to occur frequently in actively transcribed chromosomal
regions, within genes or at their immediate vicinity. Recently,
sequence analysis of 68 viral–host junctions from 60 HCCs pro-
vided evidence for cellular coding regions within several kilo-
bases in 90% of the cases [106]. Moreover, it was shown that
HBV integration often targets gene families involved in cell sur-
vival, proliferation and immortalization, such as hTERT, PDGF
receptor, MLL, calcium signaling-related genes and 60s ribosomal
protein genes. Indeed, recurrent viral insertions nearby the hTERT
or MLL gene have been reported by different groups [106,109–
111]. It can be envisaged that viral insertion induces the ﬁrst
genetic hit in liver tumourigenesis and that different genes tar-
geted by viral integration play important role in hepatocarcino-
genesis. While enhanced expression of some cellular target
genes upon nearby viral insertion has been documented, the
question of whether these genes play a role in tumourigenesisJournal of Hepatology 201as drivers or represent only bystanders has rarely been
addressed. Finally, although integrated viral sequences are defec-
tive for replication, they might also contribute ‘‘in trans” to tumo-
urigenesis through the production of truncated and mutated HBx
or preS2/S proteins. These proteins may act on HCC development
by disrupting the control of cellular gene expression or by acti-
vating oncogenic signaling pathways.
Besides acting by cis- or trans-activation, HBV insertions have
been associated with major genetic alterations within the cell
genome, including large deletions, duplications and chromo-
somal translocations [112–116]. The association of HBV integra-
tion with large genomic changes might reﬂect the abrogation of
control mechanisms that safeguard chromosomal integrity [49].The HBx regulatory protein: a viral oncogene?
The HBx protein encoded by the X gene has been designated
‘‘viral oncoprotein” by several authors. This protein has been
involved in liver cell transformation because of its pleiotropic
activities on cell cycle regulation, signaling pathways and DNA
repair (reviewed in [117–119]) (Fig. 4). However, evidence for a
direct transforming activity of HBx is scarce. HBx has been
reported to transform two cell lines immortalized by the simian
virus 40 large T antigen (SV40TAg) [120,121]. The viral protein
has also been shown to cooperate with Ras in the transformation
of primary human ﬁbroblasts, either by activating the phosphati-
dylinositol-3 kinase and Akt pathway or by overcoming Ras-
induced senescence [122,123]. A weak tumourigenicity has been
attributed to HBx in TGF-a immortalized murine hepatocytes, but
no cooperation could be evidenced with mutated p53 [124].
Other studies describe opposite effects, in which the apoptotic
properties of HBx suppress transformation of primary rodent
ﬁbroblasts by different oncogenes [125]. One caveat with these
observations is that most were made in cell culture with high lev-
els of X gene expression. Indeed, in the chronically infected liver,
HBx expression is kept at low, barely detectable levels [126].
Studies of HBx oncogenicity in transgenic mice have yielded
divergent results that may be related to different murine genetic
backgrounds and various promoters yielding different expression
levels of the viral protein. HCC development has been associated
with high-level hepatic expression of HBx in a transgenic mouse
linegenerated in theoutbredCD-1background [127]. Inmostother
transgenic lines in different backgrounds, expression of HBx by
itself did not lead to HCC development, although slight histopath-
ologic alterations could be observed in the liver [128]. Transgenic
expression of HBx in the murine liver activates both proliferation
and apoptosis, and sensitizes hepatocytes to oncogenic transfor-
mation [129–133]. Consistentwith the ability of HBx to deregulate
the cell cycle, premature cell cycle entry or impaired regeneration
has been observed after partial hepatectomy of the liver of HBx
mice from different transgenic lines [134–136].
Among the different activities of HBx, its trans-activation
function may play a crucial role in hepatocarcinogenesis because
it is involved in the activation of a large number of signaling
pathways and cellular genes that are involved in oncogenesis,
proliferation, inﬂammation and immune responses [137–139].
In particular, we have recently shown that HBx interacts with
the acetyltransferases CBP/p300, and that this interaction plays
a decisive role in the activation of CREB-dependent transcription
[140]. The activation of CREB/ATF trans-activation function by0 vol. 52 j 594–604 599
Fig. 4. Multiple biological activities of HBx. HBx binds various transcription factors, coactivators and components of the basal transcription machinery and participates
directly in the control of viral and cellular transcription. HBx can also regulate transcription indirectly by acting on cellular signaling pathways such as NF-jB, MAPKs and
JAK/STAT. Moreover, HBx may play a role in protein degradation and in apoptosis via its interaction with proteasome subunits, mitochondrial proteins, DDB1 and p53.
ReviewHBx appears double since HBx has been shown to increase CREB/
ATF DNA-binding afﬁnity as well as to enhance the recruitment of
CBP/p300 to CREB/ATF bound to cellular DNA [140,141] (Fig. 5).
The modulation of CREB/ATF activity by HBx represents an
important aspect of HBx activities since the CREB/ATF family
members play an essential role in liver metabolism and prolifer-
ation, and CREB has been implicated in hepatocarcinogenesis
[142]. Moreover, the coactivators CBP/p300 are known to bind
and activate a large variety of cellular transcription factors
[143]. Some of these factors, such as c-Jun, c-Fos and NF-jB are600 Journal of Hepatology 201also activated by HBx, and the interaction between HBx and
CBP/p300 could explain, at least partially, the broad activity of
HBx on transcription.
Another reported activity of HBx targets centrosome dynam-
ics and mitotic spindle formation through the binding of HBx
with different cellular partners implicated in centrosome forma-
tion. HBx has been shown to bind and partially inactivate BubR1,
an effector of multiple mitotic kinases that speciﬁes microtubule
attachments and checkpoint functions [144]. HBx also interacts
with HBXIP, a major regulator of centrosome duplication,0 vol. 52 j 594–604
Fig. 5. Modulation of CREB transcriptional activity by HBx. HBx interacts with
the acetyltransferases CBP/p300 and PCAF, and favors recruitment of these
coactivators onto CREB-responsive promoters, leading to the activation of gene
expression.
JOURNAL OF HEPATOLOGYrequired for bipolar spindle formation and cytokinesis [145].
Interestingly, recent data have linked DNA re-replication induced
by HBx to partial polyploidy, known to be associated with cancer
pathogenesis [146]. Although the precise HBx activities that
interfere with the mitotic cell cycle remain to be determined,
these data provide a strong link between HBx expression and
chromosomal instability in HBV-related carcinogenesis.Conclusions and perspectives
Consistent with the multifactorial aetiology of HCC and the
long latency period of tumour formation, a large variety of
oncogenes, growth factors and tumour suppressors have been
implicated in human hepatocarcinogenesis [49,51]. The ques-
tion of whether HBV and other aetiological factors and co-fac-
tors may trigger different tumourigenic pathways can now be
addressed, owing to the development of novel technologies
for genome-wide scans of genetic alterations and gene expres-
sion, and to new technologies in proteomic analysis. Increased
frequency of p53 mutations in HCC has been associated with
AFB1 exposure and chronic HBV infection, while HBV-related
tumours display high chromosomal instability and low rate of
b-catenin mutation. So far, studies have mainly been focused
on tumours; it will therefore be important to analyze gene
expression and proteomic changes in large series of samples
from chronic hepatitis B at different stages in order to identify
suitable prognostic markers and therapeutic targets. Besides
genomic alterations, epigenetic factors like methylation-associ-
ated gene silencing and altered expression of microRNAs may
play an important role in the deregulation of cellular functions
leading to malignant transformation, and they warrant atten-
tion. Better understanding of the complex role of HBV in liver
tumourigenesis will undoubtedly contribute to improve the
management of liver diseases induced by chronic hepatitis B.
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